Floatz logo

Therapeutic Asset Ratings

5,108 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Aspirin
Cerebral Atherosclerosis
Population Health Research InstituteP3BB (64)
Astx727
Acute Myeloid Leukemia
M.D. Anderson Cancer CenterP3BB (64)
Ataluren
Duchenne Muscular Dystrophy
PTC TherapeuticsP3BB (64)
Atezolizumab
Bile Duct Adenocarcinoma
Georgetown UniversityP3BB (64)
Atezolizumab
Differentiated Thyroid Carcinoma
ExelixisP3BB (64)
Atezolizumab
Urethra Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3BB (64)
Atezolizumab
Colon Carcinoma
Baylor College of MedicineP3BB (64)
Av-Gbm-1
Glioblastoma
Aivita Biomedical, Inc.P3BB (64)
Azacitidine
T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P3BB (64)
Azacytidine
Myelodysplastic Syndrome
Janssen Research & Development, LLCP3BB (64)
bay94-9027
Hemorrhagic Disease
BayerP3BB (64)
Bcd-217
Metastatic Melanoma
BiocadP3BB (64)
Begev
Classic Hodgkin Lymphoma
Cairo UniversityP3BB (64)
Belrestotug
Non-Small Cell Lung Carcinoma
GlaxoSmithKlineP3BB (64)
Belzutifan
Von Hippel-Lindau Disease
Merck Sharp & Dohme LLCP3BB (64)
Bendamustine
Marginal Zone Lymphoma
Henan Cancer HospitalP3BB (64)
Bgb-43395
Hormone Receptor-Positive Breast Cancer
BeOne MedicinesP3BB (64)
Bleomycin
Malignant Germ Cell Tumor Of Ovary
Children's Oncology GroupP3BB (64)
Bleomycin
Ovarian Embryonal Carcinoma
Children's Oncology GroupP3BB (64)
Bleomycin
Ovarian Yolk Sac Tumor
Children's Oncology GroupP3BB (64)
Bleomycin
Testicular Embryonal Carcinoma
Children's Oncology GroupP3BB (64)
bnt323
Breast Cancer
BioNTech SEP3BB (64)
Bortezomib
T-Cell Childhood Acute Lymphocytic Leukemia
National Cancer Institute (NCI)P3BB (64)
Bortezomib
Non-Hodgkin Lymphoma
OHSU Knight Cancer InstituteP3BB (64)
Busulfanum
Acute Myeloid Leukemia With Multilineage Dysplasia
National Cancer Institute (NCI)P3BB (64)
Showing 1601 to 1625 of 5,108 assets
PreviousPage 65 of 205Next